The contraceptive market is anticipated to be valued at USD 19.79 billion in 2024 and registering a CAGR of 5.5% from 2024 to 2034. The market is foreseen to reach USD 33.79 billion by 2034.
Contraception, which involves preventing pregnancy using drugs or devices, is expanding due to factors such as family planning, higher education, health issues, and increased awareness of modern contraception.
| Attributes | Details |
|---|---|
| Market Value for 2024 | USD 19.79 billion |
| Market Value for 2034 | USD 33.79 billion |
| Market Forecast CAGR for 2024 to 2034 | 5.5% |
Explore FMI!
Book a free demo
The contraceptive market has historically developed at a CAGR of 3.9%. However, sales have advanced at a trivial pace, displaying a CAGR of 5.5% from 2024 to 2034.
| Attributes | Details |
|---|---|
| Market Historical CAGR for 2019 to 2023 | 3.90% |
Long-term use of birth control medications can cause side effects such as bleeding, headaches, nausea, and weight gain. The low adoption of contraception in developing countries is due to a lack of awareness and social taboos.
Alternative methods like condoms and IUDs, which are effective without side effects, also contribute to the low adoption rate of these drugs. Healthcare providers and facility managers face challenges integrating human rights into contraception services, ensuring high quality, autonomy, and respectful care.
The global pandemic has particularly impacted market growth, leading to a drop in device sales due to strict lockdown regulations. The family planning industry has been significantly impacted by the global pandemic, causing a slow recovery due to a lack of raw materials, workforce, and new consignments.
Clinical trials are anticipated to introduce new contraception pills and gels to address new laws and limitations on current birth control procedures. The focus is on developing a non-hormonal pill to expand men's birth control options.
Widespread Demand for Wearable Pregnancy Devices
Adoption of Hormonal Contraception Simplifies the Pregnancy Scare
Rise in Government Initiatives for Promoting Access to Family Planning
The following part offers an in-depth analysis of segments of the contraceptive market. The demand for drugs is significant, whereas the need for female contraceptive is anticipated to increase in 2024.
| Attributes | Details |
|---|---|
| Top Product Type | Drug |
| Market share in 2024 | 41.50% |
The demand for contraceptive drugs is experiencing a 41.50% market share growth in 2024 due to augmented family planning and contraception efforts.
| Attributes | Details |
|---|---|
| Top Gender | Female |
| Market share in 2024 | 74.70% |
The demand for contraceptives for female patients is augmented, with a market share of 74.70% in 2024. Because female contraception techniques are more effective at preventing conception than male contraception, they are more widely used.
Based on the statistical data, industries in China and Germany are developing relatively in the upcoming decade. Simultaneously, the contraception industry in the United States and India is hitting the roof. The contraceptive sector in the ANZ region is anticipated to climb gradually in the upcoming decade.
| Countries | CAGR from 2024 to 2034 |
|---|---|
| United States | 5.80% |
| Germany | 5.50% |
| China | 6.10% |
| India | 5.80% |
| Australia and New Zealand | 5.10% |
The United States is anticipated to hold a CAGR of 5.8% from 2024 to 2034 in the contraceptive market.
In the United States, abstinence-only sex education is the primary form of sexual education, promoting abstinence from sex outside marriage or premarital sex in 39 states and the District of Columbia. However, this often excludes essential birth control measures and safe sex practices, contributing to an increase in teenage pregnancy rates due to the lack of comprehensive sex education.
Lack of accurate sex education in schools can hinder the adoption of products like female condoms, hindering market growth in the United States. Youth may remain unaware of these products, leading to their inability to use them. Therefore, it is essential to prioritize comprehensive sexual education in schools to empower young individuals to make decisions about their sexual health.
Demand for contraception devices in Germany is estimated to develop at a CAGR of 5.5%, with firms developing innovative solutions for birth control.
Germany's public health insurance is highly profitable, covering various health services, including birth control for women under 22. This provision ensures affordable and reliable contraception, allowing young women to make decisions about their reproductive health.
Germany's high prevalence of contraception use is attributed to its exceptional access to online information and average availability of contraception supplies, with most women using some form of birth control.
Germany achieved a 75.1 score in the 2020 European Contraception Policy Atlas, highlighting its commitment to providing comprehensive and accessible reproductive health services to its citizens.
China is on the brink of a significant market expansion in contraceptive devices and drugs, with a projected CAGR of 6.1% from 2024 to 2034.
Oral contraception, also known as birth control tablets or "the pill," is a popular form of contraception in China. These synthetic hormones, typically estrogen and progestin, limit ovulation and egg release, improving women's reproductive health and providing a safe and practical method of pregnancy avoidance.
China's oral contraceptives are highly effective, with less than one in 100 women experiencing unintentional pregnancy within a year of regular use, demonstrating their widespread use in the country.
China's oral contraception demand is increasing due to increased awareness, women's employment, STIs, LARC use, and Internet pharmacies.
The pandemic has impacted women's access to contraception and abortion services in the ANZ region, leading to increased unintended pregnancies and a rise in contraception demand. The demand for contraception solutions in Australia and New Zealand is anticipated to register a CAGR of 5.1% through 2034.
The contraceptive market growth is primarily compelled by increasing sexually transmitted disease cases and Australia's government's and organizations' initiatives on contraception device use.
The prevalence of sexually transmitted diseases, including HIV, Gonorrhoea, Hepatitis, HPV, and PID, is predicted to boost demand for contraception devices, particularly in Australia and New Zealand.
The demand for contraception methods in India is foreseen to experience a CAGR of 5.8% from 2024 to 2034.
India's population growth boosts family planning and contraception demand, highlighting the importance of sexual and reproductive health, particularly among women, leading to increased demand for these services.
The Indian government has implemented various programs, including the National Family Planning Programme, to promote family planning and increase access to contraception methods.
Private companies are investing in contraception research and development. For instance, Reckitt Benckiser Group sold its contraception division to Mankind Pharma for USD 13 million in March 2023, providing access to various contraception, including the Durex brand.
The market is a competitive and rapidly evolving industry. Key players focus on diverse techniques to stay ahead of the competition and augment their presence in the market. Effective strategies are to acquire or collaborate with companies to improve their product portfolio and market penetration.
Companies, in addition to acquisitions and collaborations, prioritize gaining FDA approvals to ensure the safety and effectiveness of their products, giving them a competitive edge over competitors who may not have received the necessary approvals.
The leading companies are well known for their innovative products and commitment to providing safe and effective contraception to women globally. By leveraging these key strategies, they are able to stay ahead of the competition and continue to grow their businesses in a rapidly evolving market.
Recent Developments in the Contraceptive Market
The market is valued at USD 19.79 billion in 2024.
The market is set to be valued at USD 33.79 billion by 2034.
In the United States, demand for contraceptive solutions is anticipated to develop a CAGR of 5.8% by 2034.
The market is to register a CAGR of 5.5% from 2024 to 2034.
Contraceptive drugs are anticipated to acquire a 41.5% market share in 2024.
Contraceptive Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
